Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2021 and provided business updates. “During the first half of 2021, the Stoke team laid the groundwork for important clinical milestones in the second half of this year,” said Edward M. Kaye, M.D., Chief Executive Of